Table 2.
DRUG DEVELOPMENT
| |||||||
---|---|---|---|---|---|---|---|
Country | No. involved in Drug Development | No. involved in Target Discovery | No. involved in Screening | No. involved in Product Development | No. involved in Clinical Trials | No. involved in Manufacturing | No. involved in M&E |
Bruneia |
- |
- |
- |
- |
- |
- |
- |
Cambodiac |
20 |
10 |
- |
2 |
- |
10 |
10 |
Indonesiab |
40 |
22 |
23 |
14 |
18 |
9 |
16 |
Laosb |
3 |
- |
- |
- |
- |
- |
- |
Malaysiab |
33 |
10 |
6 |
7 |
3 |
1 |
3 |
Myanmarc |
19 |
14 |
3 |
- |
2 |
- |
2 |
Philippinesb |
19 |
6 |
6 |
3 |
9 |
2 |
7 |
Singapored |
6 |
6 |
- |
4 |
1 |
- |
1 |
Thailandc |
90 |
59 |
- |
12 |
27 |
- |
33 |
Vietnamb |
18 |
4 |
- |
6 |
6 |
12 |
- |
DIAGNOSTICS DEVELOPMENT
| |||||||
Country |
No. involved in Diagnostics Development |
No. involved in Target Discovery |
Platform Development |
No. involved in Product Development |
No. involved in Clinical Trials |
No. involved in Manufacturing |
No. involved in M&E |
Bruneia |
- |
- |
- |
- |
- |
- |
- |
Cambodiac |
4 |
- |
- |
1 |
2 |
|
2 |
Indonesiab |
21 |
16 |
1 |
4 |
- |
2 |
18 |
Laosb |
- |
- |
- |
- |
- |
- |
- |
Malaysiab |
50 |
15 |
12 |
11 |
6 |
- |
6 |
Myanmarc |
2 |
- |
- |
- |
1 |
- |
1 |
Philippinesb |
13 |
11 |
|
8 |
6 |
2 |
1 |
Singaporee |
5/546 |
5 |
4 |
- |
- |
- |
5 |
Thailandc |
31 |
6 |
8 |
3 |
- |
- |
15 |
Vietnamb |
7 |
4 |
5 |
4 |
1 |
2 |
- |
VACCINES DEVELOPMENT
| |||||||
Country |
No. involved in Vaccine Development |
No. involved in Target Discovery |
No. involved in Screening |
No. involved in Vaccine Development |
No. involved in Clinical Trials |
No. involved in Manufacturing |
No. involved in M&E |
Bruneia |
- |
- |
- |
- |
- |
- |
- |
Cambodiab |
14 |
8 |
1 |
- |
- |
- |
1 |
Indonesia |
14 |
2 |
- |
7 |
2 |
2 |
1 |
Laosa |
- |
- |
- |
- |
- |
- |
- |
Malaysiab |
9 |
4 |
- |
2 |
2 |
- |
1 |
Myanmarb |
9 |
1 |
8 |
- |
- |
- |
- |
Philippinesb |
12 |
6 |
1 |
1 |
5 |
1 |
1 |
Singaporef |
4/110 |
4 |
4 |
- |
- |
- |
- |
Thailandb |
21 |
12 |
4 |
2 |
- |
- |
5 |
Vietnamg |
6 |
- |
- |
- |
- |
5 |
- |
TRADITIONAL MEDICINE DEVELOPMENT
| |||||||
Country |
No. involved in Traditional Medicine Development |
No. involved in Target Discovery |
No. involved in Screening |
No. involved in Product Development |
No. involved in Clinical Trials |
No. involved in Manufacturing |
No. involved in M&E |
Bruneia |
- |
- |
- |
- |
- |
- |
- |
Cambodiac |
2 |
- |
- |
- |
- |
- |
- |
Indonesiab |
16 |
7 |
|
|
2 |
1 |
2 |
Laosb |
- |
- |
- |
- |
- |
|
- |
Malaysiab |
188 |
8 |
5 |
6 |
2 |
- |
2 |
Myanmarc |
- |
- |
- |
- |
- |
- |
- |
Philippinesc |
16 |
12 |
14 |
8 |
4 |
3 |
1 |
Singaporeh |
- |
- |
- |
- |
- |
- |
- |
Thailandc |
4 |
2 |
- |
2 |
- |
- |
- |
Vietnamb | 12 | 5 | 6 | 5 | 3 | 7 | - |
Sources: Scopus (Elsevier, 2010) and country reports.
aNo specific information available.
bData based on the country report.
cData from internet sources.
dAlthough based on the country report, this does not summarize the R&D in Singapore.
eThe country report states five institutions while internet sources indicate as many as 546 institutions.
fThe country report states four institutions while the internet source cites 110 institutions.
gThe involvement of institutions in the specific stage of development is not available in the supplied information.
hNo data available for Singapore.